Sarepta Therapeutics Announces Call for Applications for the 6th ...

Sarepta Therapeutics Announces Call for Applications for the 6th Annual Route 79, The Duchenne Scholarship Program · Route 79 program, applicants must be ...

Sarepta Therapeutics Archives - Jett Foundation

Sarepta Therapeutics Announces Call for Applications for the 6th Annual Route 79, The Duchenne Scholarship Program. Sarepta announces official release of ...

Sarepta Therapeutics Announces Call for Applications for the 7th ...

Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program. Business Wire. Thu, Feb 29, 2024, 6:00 ...

Press Releases | Sarepta Therapeutics, Inc. - Investor Relations

6/28/24, Sarepta Therapeutics Announces Inducement ... 3/19/24, Sarepta Therapeutics Announces Call for Applications for the 2024 LGMD Grant Award Program.

Sarepta Therapeutics Announces Third Quarter 2024 Financial ...

6, 2024-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in ... To report SUSPECTED ADVERSE REACTIONS, contact Sarepta Therapeutics, Inc. at ...

Sarepta Therapeutics Announces Call for Applications for the 2024 ...

(NASDAQ:SRPT) the leader in precision genetic medicine for rare diseases, today announced the opening of the LGMD Grant Award Program for 2024.

Sarepta Therapeutics Announces Advisory Committee Meeting Will ...

Sarepta Therapeutics Announces Call for Applications for the 6th Annual Route 79, The Duchenne Scholarship Program. February 28, 2023. Avidity Provides Update ...

Sarepta Therapeutics to Announce Third Quarter 2024 Financial ...

6, 2024 . Subsequently, at 4:30 p.m. E.T. , the Company will host a conference call to discuss its third quarter 2024 financial results. The ...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq ...

--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...

Sarepta Therapeutics Announces Expanded US FDA Approval of ...

Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above · Please contact SareptAssist by ...

Sarepta Announces Discontinuation of SRP-5051 Development for ...

Sarepta Halts Development, Testing of DMD Therapy SRP-5051

“The decision to discontinue this program has no impact on our other approved therapies and/or clinical study programs, including Sarepta's PMO ...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq ...

How many development programs does Sarepta Therapeutics (SRPT) currently have? ... SRPT Latest News. Nov 6, 2024. Sarepta Therapeutics ...

Investor Relations | Sarepta Therapeutics, Inc.

The Investor Relations website contains information about Sarepta Therapeutics, Inc.'s business for stockholders, potential investors, and financial ...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq ...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ; November 7th, 3:34 am, +27%, $167.00, $152.00 (+10%) ; October 21st, 6:15 ...

Sarepta Therapeutics Announces Third Quarter 2024 Financial ...

Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments. Business Wire. Wed, Nov 6, 2024, 1:05 PM ...

Sarepta Therapeutics - X.com

On our #Q3Results call, Chief Customer Officer Dallan Murray shared details on an impressive third quarter, led by the continued strength of our gene therapy ...

Sarepta Therapeutics Announces Topline Results from EMBARK, a ...

– Sarepta to host investor call on October 30 at 4:30 p.m. Eastern time ... applications we use to assess particular safety or efficacy ...

FDA Expands Approval of Sarepta Therapeutics' Elevidys for the ...

Regarding current treatment for DMD, steroids have demonstrated improvement in muscle strength and function for patients aged 6 months to 2 ...

Sarepta Therapeutics - Wikipedia

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, ...